Abstract: Provided is a serial-type planar heat-generating heater and a manufacturing method thereof. In particular, the present invention relates to a serial-type planar heat-generating heater, which is capable of maximizing the effect of heating by minimizing dead zones in which heat is not generated, achieving a maximum power output in a limited area, unlike in a parallel-type heater, and achieving high temperature uniformity in all of heat-generating surfaces of the planar heat-generating heater, is easy to design to control heating performance, and may be manufactured at low costs; and a manufacturing method thereof.

Abstract: A coil component includes a body having one surface and the other surface, opposing each other, both lateral surfaces respectively connecting the one surface and the other surface and opposing each other, and both end surfaces respectively connecting the both lateral surfaces and opposing each other; a coil unit disposed in the body; a first external electrode and a second external electrode, respectively connected to the coil unit and disposed to be spaced apart from each other on the one surface of the body; and a first insulating layer covering the other surface of the body, the both lateral surfaces of the body, and the both end surfaces of the body.

Abstract: The present invention relates to a series of novel phenylaminopyridine derivatives and a use thereof for inhibiting capsid assembly and for preventing or treating virus infectious diseases thereby.

Abstract: The present invention relates to an anti-hepatitis B virus (HBV) composition containing ciclopirox or a pharmaceutically acceptable salt thereof; a pharmaceutical composition for preventing or treating an HBV-induced disease, which contains ciclopirox or a pharmaceutically acceptable salt thereof; a method for treating an HBV-induced disease, which includes a step of administering the pharmaceutical composition to a subject; and a health functional food composition for preventing or improving an HBV-induced disease, which contains ciclopirox or a physiologically acceptable salt thereof. The present invention has newly elucidated the HBV-inhibiting effect of ciclopirox, and overcame the problem of the existing drugs that cccDNA cannot be removed by monotherapy. In addition, the present invention provides a therapeutic agent capable of effectively inhibiting HBV by inhibiting core assembly during the life cycle of the virus.

Abstract: The present application relates to a pharmaceutical composition containing compound 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4-3H)-quinazolinone, and a pharmaceutically acceptable salt thereof for preventing and treating liver cancer, and the composition of the present application inhibits ROS-PI3K-AKT-TERT signal transduction, and thus can be favorably used in the treatment of a liver cell cancer, in which a protein involved in the signal transduction is overexpressed, especially, advanced liver cell cancer.

Abstract: The present application relates to a pharmaceutical composition containing compound 5-fluoro-3-phenyl-2-[(15)-1-(7H-purin-6-ylamino)propyl]-4-3H)-quinazolinone, and a pharmaceutically acceptable salt thereof for preventing and treating liver cancer, and the composition of the present application inhibits ROS-PI3K-AKT-TERT signal transduction, and thus can be favorably used in the treatment of a liver cell cancer, in which a protein involved in the signal transduction is overexpressed, especially, advanced liver cell cancer.

Abstract: Provided is a method of purifying monosilane. More particularly, the method includes removing impurities from a crude material containing monosilane and ethylene by fractional distillation (operation 1), and removing ethylene and residual impurities by passing the crude material purified in operation 1 through activated carbon (operation 2). According to the method, high-purity monosilane may be more simply and effectively obtained without additional production of byproducts by selectively adsorbing ethylene, which is difficult to separate by fractional distillation, using an activated carbon.

Abstract: Provided is a method of purifying monosilane. More particularly, the method includes removing impurities from a crude material containing monosilane and ethylene by fractional distillation (operation 1), and removing ethylene and residual impurities by passing the crude material purified in operation 1 through activated carbon (operation 2). According to the method, high-purity monosilane may be more simply and effectively obtained without additional production of byproducts by selectively adsorbing ethylene, which is difficult to separate by fractional distillation, using an activated carbon.